NEW YORK, NY / ACCESSWIRE / September 30, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
BIDU Shareholders Click Here: https://www.zlk.com/pslra-1/baidu-inc-information-request-form-2?prid=9688&wire=1
CLNC Shareholders Click Here: https://www.zlk.com/pslra-1/colony-credit-real-estate-inc-information-request-form?prid=9688&wire=1
NXTC Shareholders Click Here: https://www.zlk.com/pslra-1/nextcure-inc-information-request-form?prid=9688&wire=1
* ADDITIONAL INFORMATION BELOW *
Baidu, Inc. (NASDAQ:BIDU)
BIDU Lawsuit on behalf of: investors who purchased April 8, 2016 - August 13, 2020
Lead Plaintiff Deadline : October 19, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/baidu-inc-information-request-form-2?prid=9688&wire=1
According to the filed complaint, during the class period, Baidu, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Baidu misrepresented the financial and business condition of iQIYI; (2) iQIYI had inadequate controls; and (3) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.
Colony Credit Real Estate, Inc. (NYSE:CLNC)
This lawsuit is on behalf of persons and/or entities who purchased or otherwise acquired the common stock of Colony Credit pursuant and/or traceable to the Company's false and/or misleading Registration Statement and Prospectus issued in connection with the combination of Colony NorthStar, Inc., NorthStar Real Estate Income Trust, Inc., and NorthStar Real Estate Income II, Inc. on or about February 1, 2018 (the "Merger").
Lead Plaintiff Deadline : November 9, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/colony-credit-real-estate-inc-information-request-form?prid=9688&wire=1
According to the filed complaint, (i) the credit quality of certain of the Company's assets had deteriorated prior to the Merger, and were continuing to deteriorate at the time of the Merger; (ii) certain of the Company's loans, including four loans of approximately $261 million related to a New York hotel, were substantially impaired, there was insufficient collateral to secure the loans, and it was unlikely that the loans would be repaid; (iii) as a result, the valuation attributed to certain of the Company's assets was overstated; (iv) that certain of the assets contributed as part of the Merger were of substantially lower value than reflected in the Company's financial statements and the Registration Statement; (v) as a result, the Company's financial condition, including its book value, was materially overstated; and (vi) as a result of the foregoing, the positive statements in the Registration Statement about the Company's business, operations, and prospect were materially misleading and/or lacked a reasonable basis.
Nextcure, Inc. (NASDAQ:NXTC)
The Nextcure lawsuit was filed on behalf of investors who purchased Nextcure, Inc. (NASDAQ: NXTC) securities: (1) between November 5, 2019 and July 14, 2020, inclusive; and/or (2) pursuant or traceable to the company's secondary public offering declared effective on November 14, 2019.
Lead Plaintiff Deadline : November 20, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/nextcure-inc-information-request-form?prid=9688&wire=1
Throughout the class period defendants' statements were materially misleading because the data Defendants possessed on its principle product candidate, NC318, showed a lack of efficacy and objective responses. Had the truth been revealed, the market would have seen that NC318 was not, in fact, effective in treating most tumor types, that the NC318 application was proving to be limited (if even useful at all), and, as a result, there was a significant realizable risk that NC318 would not be nearly as popular as then-existing blockbuster drugs, such as Keytruda.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP